1. Home
  2. TYRA vs CENTA Comparison

TYRA vs CENTA Comparison

Compare TYRA & CENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$28.28

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Central Garden & Pet Company Nonvoting

CENTA

Central Garden & Pet Company Nonvoting

HOLD

Current Price

$38.29

Market Cap

2.3B

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYRA
CENTA
Founded
2018
1955
Country
United States
United States
Employees
N/A
6000
Industry
Biotechnology: Pharmaceutical Preparations
Consumer Specialties
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.3B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TYRA
CENTA
Price
$28.28
$38.29
Analyst Decision
Strong Buy
Hold
Analyst Count
11
4
Target Price
$47.50
$36.75
AVG Volume (30 Days)
807.7K
278.8K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.60
Revenue Next Year
N/A
$2.04
P/E Ratio
N/A
$13.52
Revenue Growth
N/A
N/A
52 Week Low
$8.98
$25.97
52 Week High
$40.65
$38.76

Technical Indicators

Market Signals
Indicator
TYRA
CENTA
Relative Strength Index (RSI) 42.75 67.41
Support Level $27.40 $31.21
Resistance Level $31.57 N/A
Average True Range (ATR) 1.98 0.97
MACD 0.26 0.22
Stochastic Oscillator 42.12 82.05

Price Performance

Historical Comparison
TYRA
CENTA

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About CENTA Central Garden & Pet Company Nonvoting

Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.

Share on Social Networks: